Cardiovascular involvement in patients affected by acromegaly: An appraisal

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 1712-1718

  Mosca, Susanna ^a   Paolillo, Stefania ^a   Colao, Annamaria ^a   Bossone, Eduardo ^b   Cittadini, Antonio ^a   Iudice, Francesco Lo ^a   Parente, Antonio ^a   Conte, Sirio ^a   Rengo, Giuseppe ^c   Leosco, Dario ^a   Trimarco, Bruno ^a   Filardi, Pasquale Perrone ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c IRCCS   (Italy)

Author keywords

Acromegalic cardiomyopathy; Acromegaly; GH IGF I excess; Premature atherosclerosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; TRIACYLGLYCEROL;

ACROMEGALY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE MEASUREMENT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; ENDOCRINE SURGERY; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THERAPY EFFECT; TRANSSPHENOIDAL ADENECTOMY; TREATMENT RESPONSE; VALVULAR HEART DISEASE;

ACROMEGALIC CARDIOMYOPATHY; ACROMEGALY; GH/IGF-I EXCESS; PREMATURE ATHEROSCLEROSIS;

ACROMEGALY; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMAN GROWTH HORMONE; HUMANS; RISK FACTORS;

EID: 84883277849     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.109     Document Type: Review

References (84)

1. S. Melmed Acromegaly N Engl J Med 322 1990 966 977
2. A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic complications of acromegaly: epidemiology, pathogenesis, and management Endocr Rev 25 2004 102 152
3. J.D.N. Nabarro Acromegaly Clin Endocrinol 26 1987 481 512
4. C. Rajasoorya, I.M. Holdaway, P. Wrightson, D.G. Scott, and H.K. Ibbertson Determinants of clinical outcome and survival in acromegaly Clin Endocrinol 41 1994 95 102
5. H. Ohtsuka, I. Komiya, T. Aizawa, and T. Yamada Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production Endocr J 42 1995 781 787
6. G. Minniti, C. Moroni, and M.L. Jaffrain-Rea Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients Clin Endocrinol 55 2001 307 313
7. A. Colao, D. Ferone, and P. Marzullo Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly J Clin Endocrinol Metab 86 2001 2779 2786
8. J.V. Souadjian, and A. Schirger Hypertension in acromegaly Am J Med Sci 254 1967 629 633
9. G. Vitale, R. Pivonello, and R.S. Auriemma Hypertension in acromegaly and in the normal population: prevalence and determinants Clin Endocrinol 63 2005 470 476
10. J.R. Sowers Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology Hypertension 29 1997 691 699
11. T.K. Hansen, J. Moller, and K. Thomsen Effects of growth hormone on renal tubular handling of sodium in healthy humans Am J Physiol Endocrinol Metab 281 2001 E1326 E1332
12. J. Moller, J.O. Jorgensen, J. Marqversen, E. Frandsen, and J.S. Christiansen Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor Clin Endocrinol 52 2000 181 186
13. D. Rizzoni, E. Porteri, and A. Giustina Acromegalic patients show the presence of hypertropic remodeling of subcutaneous small resistance arteries Hypertension 43 2004 561 565
14. S. Kasayama, M. Otsuki, and M. Takagi Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients Clin Endocrinol 52 2000 549 555
15. T. Ikeda, H. Terasawa, and M. Ishimura Correlation between blood pressure and plasma insulin in acromegaly J Int Med 234 1993 61 63
16. M. Bondanelli, M.R. Ambrosio, P. Franceschetti, A. Margutti, G. Trasforini, and E.C. degli Uberti Diurnal rhythm of plasma catecholamines in acromegaly J Clin Endocrinol Metab 84 1999 2458 2467
17. V. Weiss, K. Sonka, and M. Pretl Prevalence of the sleep apnea syndrome in acromegaly population J Endocrinol Invest 23 2000 515 519
18. P. Lanfranchi, and V.K. Somers Obstructive sleep apnea and vascular disease Respir Res 2 2001 315 319
19. A. Colao, R. Baldelli, and P. Marzullo Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy J Clin Endocrinol Metab 85 2000 193 198
20. B.A. Bengtsson, S. Eden, I. Ernest, A. Oden, and B. Sjogren Epidemiology and long-term survival in acromegaly Acta Med Scand 223 1988 327 335
21. J.A.H. Wass, A.G. Cudworth, G.F. Bottazzo, J.C. Woodrow, and G.M. Besser An assessment of glucose intolerance in acromegaly and its response to medical treatment Clin Endocrinol 12 1980 53 59
22. E.A. Nikkila, and R. Pelkonen Serum lipids in acromegaly Metabolism 24 1975 829 838
23. K.C. Tan, S.W. Shiu, E.D. Janus, and K.S. Lam LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I Atherosclerosis 129 1997 59 65
24. V. Hainer, A. Zak, E. Sindelkova, V. Wernischova, H. Belikovova, and J. Skorepa Elevation of high density lipoproteins in acromegalics after lisuride treatment Horm Metab Res 17 1985 220 221
25. L. Boero, M. Manavela, and L. Gómez Rosso Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly Clin Endocrinol 70 2009 88 95
26. L. Boero, M. Manavela, T. Meroño, P. Maidana, L.G. Rosso, and F. Brites Gh levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly Clin Endocrinol 77 Apr 17 2012 579 585
27. M. Arosio, G. Sartore, C.M. Rossi, G. Casati, G. Faglia, and E. Manzato LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group Atherosclerosis 151 2000 551 557
28. G.F. Maldonado Castro, H.F. Escobar-Morreale, and H. Ortega Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly Clin Endocrinol 53 2000 313 319
29. L. Boero, L. Cuniberti, and N. Magnani Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly Clin Endocrinol 72 2010 654 660
30. T.B. Twickler, G.M. Dallinga-Thie, P.M. Zelissen, H.P. Koppeschaar, and D.W. Erkelens The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients Clin Endocrinol 55 2001 69 75
31. M. Baykan, C. Erem, and O. Gedikli Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly Med Princ Pract 18 2009 228 232
32. I. Kartal, H. Oflaz, and B. Pamukçu Investigation of early atherosclerotic changes in acromegalic patients Int J Clin Pract 64 2010 39 44
33. G. Brevetti, P. Marzullo, and A. Silvestro Early vascular alterations in acromegaly J Clin Endocrinol Metab 7 2002 3174 3179
34. C. Courville, and V.R. Mason The heart in acromegaly Arch Intern Med 61 1938 704 713
35. J.T. Lie, and S.J. Grossman Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients Am Heart J 100 1980 41 52
36. S. Cannavo, B. Almoto, and G. Cavalli Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography J Clin Endocrinol Metab 91 2006 3766 3772
37. F. Bogazzi, L. Battolla, and C. Spinelli Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study J Clin Endocrinol Metab 92 2007 4271 4277
38. H. Akutsu, J. Kreutzer, and G. Wasmeier Acromegaly per se does not increase the risk for coronary artery disease Eur J Endocrinol 162 2010 879 886
39. S. Fazio, A. Cittadini, and D. Sabatini Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study Eur Heart J 14 1993 26 33
40. J.J. Hunter, and K.R. Chien Signalling pathways for cardiac hypertrophy and failure N Engl J Med 341 1999 1276 1283
41. A. Colao, B. Merola, D. Ferone, and G. Lombardi Acromegaly J Clin Endocrinol Metab 82 1997 2777 2781
42. S. Fazio, A. Cittadini, and B. Biondi Cardiovascular effects of short-term growth hormone hypersecretion J Clin Endocrinol Metab 85 2000 179 182
43. S. Fazio, A. Cittadini, and A. Cuocolo Impaired cardiac performance is a distinct feature of uncomplicated acromegaly J Clin Endocrinol Metab 79 1994 441 446
44. L. Saccà, A. Cittadini, and S. Fazio Growth hormone and the heart Endocr Rev 15 1994 555 573
45. R. Baldelli, E. Ferretti, and M.L. Jaffrain-Rea Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients J Clin Endocrinol Metab 84 1999 527 532
46. J. Hradec, J. Kral, and T. Janota Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) Am J Cardiol 83 1999 1506 1509
47. L. Saccà, R. Napoli, and A. Cittadini Growth hormone, acromegaly, and heart failure: an intricate triangulation Clin Endocrinol 59 2003 660 671
48. A. Colao, P. Marzullo, C. Di Somma, and G. Lombardi Growth hormone and heart Clin Endocrinol 54 2001 137 154
49. D. Capalbo, A. Lo Vecchio, and V. Farina Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study J Clin Endocrinol Metab 94 2009 3347 3355
50. G. Ohtsuka, S. Aomi, and H. Koyanagi Heart valve operation in acromegaly Ann Thorac Surg 64 1997 390 393
51. E. Rabkin, M. Aikawa, J.R. Stone, Y. Fukumoto, P. Libby, and F.J. Schoen Activated myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves Circulation 104 2001 2525 2532
52. A. Colao, L. Spinelli, and P. Marzullo High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study J Clin Endocrinol Metab 88 2003 3196 3201
53. A.M. Pereira, S.W. van Thiel, and J.R. Lindner Increased prevalence of regurgitant valvular heart disease in acromegaly J Clin Endocrinol Metab 89 2004 71 75
54. A.A. van der Klaauw, J.J. Bax, and F. Roelfsema Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation Growth Horm IGF Res 16 2006 101 107
55. A. Colao, J. Marek, and M.I. Goth No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly J Clin Endocrinol Metab 93 2008 2243 2248
56. B. Surawicz, and M.L. Mangiardi Electrocardiogram in endocrine and metabolic disorders Cardiovasc Clin 8 1977 243 266
57. G. Kahaly, K.V. Olshausen, and S. Mohr-Kahaly Arrhythmia profile in acromegaly Eur Heart J 13 1992 51 56
58. E.A. Rodrigues, M.P. Caruana, A. Lahiri, J.D. Nabarro, H.S. Jacobs, and E.B. Raftery Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle Br Heart J 62 1989 185 194
59. P. Maffei, C. Martini, and A. Milanesi Late potentials and ventricular arrhythmias in acromegaly Int J Cardiol 104 2005 197 203
60. B.L. Herrmann, C. Bruch, and B. Saller Occurrence of ventricular late potentials in patients with active acromegaly Clin Endocrinol 55 2001 201 207
61. L.M. Kozer, K.M. Cheriparambil, D.R. Schifter, B.I. Saul, and C.V. Reddy Clinical significance of variability of ventricular late potentials detected before discharge in patients after myocardial infarction Am Heart J 139 2000 134 141
62. M.B. Simson Noninvasive identification of patients at high risk for sudden cardiac death. Signal-averaged electrocardiography Circulation 85 1992 145 151
63. M. Stelmachowska-Banaś, G. Zieliński, P. Zdunowski, J. Podgórski, and W. Zgliczyński The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly Neurol Neurochir Pol 45 2011 328 334
64. H. Tsuchiya, T. Onishi, H. Mogami, and M. Iida Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy Endocrinol Jpn 37 1990 797 807
65. J. Oscarsson, O. Wiklund, K.E. Jakobsson, B. Petrusont, and B.A. Bengtsson Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy Clin Endocrinol 41 1994 603 608
66. A. Colao, A. Cuocolo, and P. Marzullo Is the acromegalia cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance J Clin Endocrinol Metab 86 2001 1551 1557
67. A. Colao, P. Marzullo, and D. Ferone Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly J Clin Endocrinol Metab 86 2000 3132 3140
68. J. Hradec, J. Kral, and T. Janota Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) Am J Cardiol 83 1999 1506 1509
69. P. Chanson, J. Timsit, and C. Masquet Cardiovascular effects of the somatostatin analog octreotide in acromegaly Ann Intern Med 113 1990 921 925
70. P. Maison, A.I. Tropeano, I. Macquin-Mavier, A. Giustina, and P. Chanson Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis J Clin Endocrinol Metab 92 2007 1743 1747
71. A. Colao, A. Cuocolo, and P. Marzullo Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly J Clin Endocrinol Metab 84 1999 17 23
72. G. Lombardi, A. Colao, and P. Marzullo Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a prospective multi-center study J Endocrinol Invest 25 2002 971 976
73. L.M. Fatti, M. Scacchi, and E. Lavezzi Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients Clin Endocrinol 65 2006 626 630
74. E. Couture, V. Bongard, J.C. Maiza, A. Bennet, and P. Caron Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide Pituitary 15 2012 518 525
75. M. Breidert, T. Pinzer, J. Wildbrett, S.R. Bornstein, and M. Hanefeld Long-term effect of octreotide in acromegaly on insulin resistance Horm Metab Res 27 1995 226 230
76. D. Ferone, A. Colao, A.-J. van der Lely, and S.W.J. Lamberts Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging 17 2000 81 92
77. G. Tolis, N.G. Angelopoulos, and E. Katounda Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs Neuroendocrinology 83 2006 249 257
78. C.L. Ronchi, V. Varca, and P. Beck-Peccoz Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors J Clin Endocrinol Metab 91 2006 121 128
79. R. Baldelli, C. Battista, and F. Leonetti Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment Clin Endocrinol 59 2003 492 499
80. A. Colao, R. Pivonello, and R.S. Auriemma Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance Eur J Endocrinol 154 2006 467 477
81. C. Berg, S. Petersenn, and H. Lahner Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control J Clin Endocrinol Metab 95 2010 3648 3656
82. A.L. Barkan, P. Burman, and D.R. Clemmons Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant J Clin Endocrinol Metab 90 2005 5684 5691
83. R. Pivonello, M. Galderisi, and R.S. Auriemma Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance J Clin Endocrinol Metab 92 2007 476 482
84. M.C. De Martino, R.S. Auriemma, and G. Brevetti The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues J Endocrinol Invest 33 2010 663 670